Combining cancer immunotherapy and targeted therapy

Current Opinion in Immunology

Volumn 25, Issue 2, 2013, Pages 291-296

  Ribas, Antoni ^a   Wolchok, Jedd D ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; B RAF KINASE INHIBITOR; CANCER VACCINE; DABRAFENIB; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INTERLEUKIN 17; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; VEMURAFENIB;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; DRUG RESPONSE; EPIGENETICS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CANCER; LUNG CANCER; LYMPHOCYTE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; REVIEW;

HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84877051042     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.02.011     Document Type: Review

References (53)

1. Schumacher L.Y., Ribas A. Overcoming tumor resistance to immunotherapy. Cancer Ther 2006, 4:13-26.
2. Begley J., Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008, 14:4385-4391.
3. Johnstone R.W., Licht J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell 2003, 4:13-18.
4. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X., Marks P.A. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005, 102:673-678.
5. Hadnagy A., Beaulieu R., Balicki D. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Mol Cancer Ther 2008, 7:740-748.
6. Zhang X.D., Gillespie S.K., Borrow J.M., Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 2003, 66:1537-1545.
7. Zhang X.D., Gillespie S.K., Borrow J.M., Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004, 3:425-435.
8. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., Holloway A.J., Johnstone R.W. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005, 102:3697-3702.
9. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., Altucci L., Nervi C., Minucci S., Pelicci P.G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005, 11:71-76.
10. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005, 11:77-84.
11. Natsume A., Wakabayashi T., Tsujimura K., Shimato S., Ito M., Kuzushima K., Kondo Y., Sekido Y., Kawatsura H., Narita Y., et al. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 2008, 122:2542-2553.
12. Magner W.J., Kazim A.L., Stewart C., Romano M.A., Catalano G., Grande C., Keiser N., Santaniello F., Tomasi T.B. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 2000, 165:7017-7024.
13. Maeda T., Towatari M., Kosugi H., Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000, 96:3847-3856.
14. Khan A.N., Gregorie C.J., Tomasi T.B. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 2008, 57:647-654.
15. Setiadi A.F., Omilusik K., David M.D., Seipp R.P., Hartikainen J., Gopaul R., Choi K.B., Jefferies W.A. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 2008, 68:9601-9607.
16. Konkankit V.V., Kim W., Koya R.C., Eskin A., Dam M.A., Nelson S., Ribas A., Liau L.M., Prins R.M. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med 2011, 9:192.
17. Skov S., Pedersen M.T., Andresen L., Straten P.T., Woetmann A., Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005, 65:11136-11145.
18. Armeanu S., Bitzer M., Lauer U.M., Venturelli S., Pathil A., Krusch M., Kaiser S., Jobst J., Smirnow I., Wagner A., et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005, 65:6321-6329.
19. Watanabe Y., Maekawa M. Methylation of DNA in cancer. Adv Clin Chem 2010, 52:145-167.
20. Kato Y., Yoshimura K., Shin T., Verheul H., Hammers H., Sanni T.B., Salumbides B.C., Van Erp K., Schulick R., Pili R. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 2007, 13:4538-4546.
21. Murakami T., Sato A., Chun N.A., Hara M., Naito Y., Kobayashi Y., Kano Y., Ohtsuki M., Furukawa Y., Kobayashi E. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 2008, 128:1506-1516.
22. Vo D.D., Prins R.M., Begley J.L., Donahue T.R., Morris L.F., Bruhn K.W., de la Rocha P., Yang M.Y., Mok S., Garban H.J., et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009, 69:8693-8699.
23. Christiansen A.J., West A., Banks K.M., Haynes N.M., Teng M.W., Smyth M.J., Johnstone R.W. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A 2011, 108:4141-4146.
24. Brogdon J.L., Xu Y., Szabo S.J., An S., Buxton F., Cohen D., Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
25. Reilly C.M., Mishra N., Miller J.M., Joshi D., Ruiz P., Richon V.M., Marks P.A., Gilkeson G.S. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004, 173:4171-4178.
26. Johnson J., Pahuja A., Graham M., Hering B., Hancock W.W., Bansal-Pakala P. Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques. Transplant Proc 2008, 40:459-461.
27. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., Li B., Turka L.A., Olson E.N., Greene M.I., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
28. Ribas A., Flaherty K.T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011, 8:426-433.
29. Comin-Anduix B., Chodon T., Sazegar H., Matsunaga D., Mock S., Jalil J., Escuin-Ordinas H., Chmielowski B., Koya R.C., Ribas A. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010, 16:6040-6048.
30. Hong D.S., Vence L., Falchook G., Radvanyi L.G., Liu C., Goodman V., Legos J.J., Blackman S., Scarmadio A., Kurzrock R., et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2012, 18:2326-2335.
31. Frederick D.T., Piris A., Cogdill A.P., Cooper Z.A., Lezcano C., Ferrone C.R., Mitra D., Boni A., Newton L.P., Liu C., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013, (epub).
32. Wilmott J.S., Long G.V., Howle J.R., Haydu L.E., Sharma R.N., Thompson J.F., Kefford R.F., Hersey P., Scolyer R.A. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012, 18:1386-1394.
33. Boni A., Cogdill A.P., Dang P., Udayakumar D., Njauw C.N., Sloss C.M., Ferrone C.R., Flaherty K.T., Lawrence D.P., Fisher D.E., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70:5213-5219.
34. + T cells contribute to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013, 123:1371-1381.
35. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
36. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
37. Halaban R., Zhang W., Bacchiocchi A., Cheng E., Parisi F., Ariyan S., Krauthammer M., McCusker J.P., Kluger Y., Sznol M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010, 23:190-200.
38. Su F., Viros A., Milagre C., Trunzer K., Bollag G., Spleiss O., Reis-Filho J.S., Kong X., Koya R.C., Flaherty K.T., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012, 366:207-215.
39. Callahan M.K., Rampal R., Harding J.J., Klimek V.M., Chung Y.R., Merghoub T., Wolchok J.D., Solit D.B., Rosen N., Abdel-Wahab O., et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012, 367:2316-2321.
40. Oberholzer P.A., Kee D., Dziunycz P., Sucker A., Kamsukom N., Jones R., Roden C., Chalk C.J., Ardlie K., Palescandolo E., et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012, 30:316-321.
41. Koya R.C., Mok S., Otte N., Blacketor K.J., Comin-Anduix B., Tumeh P.C., Minasyan A., Graham N., Graeber T.G., Chodon T., et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012, 72:3928-3937.
42. Liu C., Peng W., Xu C., Lou Y., Zhang M., Wargo J.A., Chen J.Q., Li H.S., Watowich S.S., Yang Y., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013, 19:393-403.
43. Hooijkaas A., Gadiot J., Morrow M., Stewart R., Schumacher T., Blank C.U. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 2012, 1:609-617.
44. + T cell memory and tumor immunity. Immunity 2011, 34:541-553.
45. + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010, 32:67-78.
46. Araki K., Turner A.P., Shaffer V.O., Gangappa S., Keller S.A., Bachmann M.F., Larsen C.P., Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108-112.
47. Srivastava R.K., Utley A., Shrikant P.A. Rapamycin: a rheostat for CD8(+) T-cell-mediated tumor therapy. Oncoimmunology 2012, 1:1189-1190.
48. Parsa A.T., Waldron J.S., Panner A., Crane C.A., Parney I.F., Barry J.J., Cachola K.E., Murray J.C., Tihan T., Jensen M.C., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007, 13:84-88.
49. Marshall N.A., Galvin K.C., Corcoran A.M., Boon L., Higgs R., Mills K.H. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-gamma+IL-17+polyfunctional T cells that mediate rejection of murine tumors. Cancer Res 2012, 72:581-591.
50. Borg C., Terme M., Taieb J., Menard C., Flament C., Robert C., Maruyama K., Wakasugi H., Angevin E., Thielemans K., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004, 114:379-388.
51. Taieb J., Chaput N., Menard C., Apetoh L., Ullrich E., Bonmort M., Pequignot M., Casares N., Terme M., Flament C., et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006, 12:214-219.
52. Balachandran V.P., Cavnar M.J., Zeng S., Bamboat Z.M., Ocuin L.M., Obaid H., Sorenson E.C., Popow R., Ariyan C., Rossi F., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011, 17:1094-1100.
53. Yang Y., Liu C., Peng W., Lizee G., Overwijk W.W., Liu Y., Woodman S.E., Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 2012, 120:4533-4543.